Record Details

Double vs. single high dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area

Hematology Reports

View Archive Info
Field Value
Authentication Code dc
Title Statement Double vs. single high dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area
Added Entry - Uncontrolled Name Hans E. Johnsen; Professor
Bo Björkstrand; MD
Tobias W. Klausen; Cand Pol
Kari Remes; MD
Astrid Gruber; MD
Lene M. Knudsen; MD
Olav J. Bergmann; MD
Stig Lenhoff; MD
Acknowledgements: Amgen, Roche, and Schering-Plough.
Uncontrolled Index Term Autologous stem cell transplantation; Multiple myeloma;
Hematology; Multiple myeloma; Treatment
Summary, etc. Autologous stem cell transplantation is still considered the standard of care in young patients with multiple myeloma (MM). This disease is the most common indication for high-dose therapy (HDT) supported by hematopoietic stem-cell transplantation and much data support the benefit of this procedure. Results of randomized studies are in favor of tandem autologous transplantation although the effect on overall survival is unclear. Based on sequential registration trials in the Nordic area, we aimed to evaluate the outcome of conventional single or double HDT. During 1994-2000 we registered a total of 484 previously untreated patients under the age of 60 years at diagnosis who on a regional basis initially were treated with single [Trial NMSG #5/94 and #7/98 (N=383)] or double [Trial Huddinge Karolinska Turku Herlev (N=101)] high-dose melphalan (200 mg/m2) therapy supported by autologous stem cell transplantation.A complete or very good partial response was achieved by 40% of patients in the singletransplant group and 60% of patients in the double-transplant group (p=0.0006). The probability of surviving progression-free for 5 years after the diagnosis was 25% (95% CL 18-32%) in the singletransplant group and 46% (95% CL 33-55%) in the double-transplant group (p=0.0014). The estimated overall five-year survival rate was 60% in the single-transplant group and 64% in the double-transplant (p=0.9). In a multivariate analysis of variables, including single versus double transplantation, b2 microglobulin level, age, sex and disease stage, only b2 microglobulin level was predictive for overall survival (p>0.0001) and progression free survival (p=0.001). In accordance with these results, a 1:1 case-control matched comparison between double and single transplantation did not identify significant differences in overall and progression free survival.In this retrospective analysis up front double transplantation with melphalan (200 mg/m2) as compared to single transplantation  did not seem to improve the final outcome among patients in the Nordic area. These data are in accordance with recent publications from the Bologna 96 trial indicating that a second transplant should not be recommended up front as standard care. 
Publication, Distribution, Etc. PAGEPress Publications
Electronic Location and Access application/pdf
Data Source Entry Hematology Reports; Vol 1, No 1 (2009); e2
Language Note en
Terms Governing Use and Reproduction Note <p>PAGEPress has chosen to apply the <a href="" target="_blank">Creative Commons Attribution License</a> (CCAL) to all manuscripts to be published. </p> <p>An Open Access Publication is one that meets the following two conditions:</p> <ol><li>The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li><li>A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li></ol> Authors who publish with this journal agree to the following terms: 1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. 3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).